Skip to main content
Download PDF
Download ePub

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation

BMC Chemistry volume 17, Article number: 58 (2023) Cite this article

Abstract

Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir and remdesivir in spiked human plasma. The UV absorption spectra of favipiravir and remdesivir have shown some overlap, making simultaneous determination difficult. Due to the considerable overlap, two ratio spectra manipulating spectrophotometric methods, namely, ratio difference and the first derivative of ratio spectra, enabled the determination of favipiravir and remdesivir in their pure forms and spiked plasma. The ratio spectra of favipiravir and remdesivir were derived by dividing the spectra of each drug by the suitable spectrum of another drug as a divisor to get the ratio spectra. Favipiravir was determined by calculating the difference between 222 and 256 nm of the derived ratio spectra, while calculating the difference between 247 and 271 nm of the derived ratio spectra enabled the determination of remdesivir. Moreover, the ratio spectra of every drug were transformed to the first order derivative using ∆λ = 4 and a scaling factor of 100. The first-order derivative amplitude values at 228 and 251.20 nm enabled the determination of favipiravir and remdesivir, respectively. Regarding the pharmacokinetic profile of favipiravir (Cmax 4.43 µg/mL) and remdesivir (Cmax 3027 ng/mL), the proposed methods have been successfully applied to the spectrophotometric determination of favipiravir and remdesivir in plasma matrix. Additionally, the greenness of the described methods was evaluated using three metrics systems: the national environmental method index, the analytical eco-scale, and the analytical greenness metric. The results demonstrated that the described models were in accordance with the environmental characteristics.

Peer Review reports

Introduction

Drug repurposing has become an attractive approach to rapidly identifying drugs that combat the spread of new infectious diseases. The emergence of the COVID-19 pandemic caused by SARS-CoV-2 has prompted the search for numerous compounds that can be reused to rapidly prevent mortality, morbidity, and the spread of this novel viral disease. Despite the rapid development of COVID-19 vaccines, their proven efficacy, and massive global vaccination campaigns, it is crucial to identify different therapeutics, including effective antivirals, to address the challenges associated with failure of immunity, rejection of vaccines, and the emergence of new SARS-CoV-2 variants [1,2,3,4,5]. Favipiravir (FPV) and remdesivir (RDV), shown in Fig. 1, are both broad-spectrum RNA polymerase inhibitors that were first approved to treat influenza and Ebola viruses, respectively. Both have shown effectiveness against SARS-CoV-2 in clinical studies and have been repurposed for the treatment of COVID-19 patients in several countries. They are antimetabolites that mimic viral genome structural features and subsequently inhibit viral replication by targeting RNA polymerase [6,7,8,9]. FPV is usually prescribed orally for mild and moderate COVID-19 cases, whereas RDV is frequently administered parenterally for severe and hospitalized cases. A study on Syrian hamsters infected with COVID-19 discovered that co-administration of FVP and the RDV reduced the virus load in the hamsters’ lungs more effectively than either drug alone [10].

FPV was reported to be quantitatively determined alone by chromatographic [11,12,13,14,15], spectrofluorimetric [12, 16], spectrophotometric [15, 17], and electrochemical techniques [18,19,20,21,22], either in pharmaceutical dosage form or plasma. In addition, FPV was determined simultaneously in plasma with molnupiravir and ritonavir using the HPTLC technique [23], with hydroxychloroquine and RDV using the spectrofluorimetric method [24, 25], with dexamethasone and RDV using the UPLC technique [26], and with RDV using the TLC-densitometric [27] and spectrofluorimetric [28] techniques. On the other hand, different analytical approaches have been reported for the quantification of RDV alone in pharmaceutical dosage form or plasma, including chromatographic [29,30,31,32,33,34], spectrofluorometric [35, 36], and spectrophotometric methods [30, 37].

Regarding the pharmacokinetic profile of FPV and RDV, the Cmax of FPV and RDV, 4.43 µg/mL and 3027 ng/mL, respectively, [24, 25, 38], are high enough to be detected spectrophotometrically in the plasma matrix. This inspired the authors to develop the first validated green spectrophotometric methods for the determination of FPV and RDV in plasma matrices. Due to the considerable overlap between the UV absorption spectra of FPV and RDV, which makes it challenging to directly resolve them in mixtures, we presented in this paper two ratio spectra manipulating spectrophotometric methods, ratio difference [39,40,41] and first derivative of ratio spectra [42, 43], for the measurement of FPV and RDV in pure forms and spiked plasma. Additionally, the greenness of the described methods was evaluated using three metrics systems, namely, the national environmental method index (NEMI) [44,45,46], the analytical eco-scale [47], and the analytical greenness metric (AGREE) [48,49,50,51,52,53,54,55,56,57,58,59,60,61].

Fig. 1
figure 1

Chemical structure of FPV and RDV

Full size image

Experimental

Materials and solvent

Pharmakeda Health Company (Egypt) provided FPV and RDV powders. Ethanol HPLC grade was supplied by Sigma-Aldrich (Germany). The National Egyptian Blood Bank provided a human plasma sample, which was kept frozen until analysis. Remdesivir-EVA PHARMA vial (100 mg RDV per 20 mL) and Avipiravir tablets (200 mg FPV per tablet) were obtained from local pharmacy.

Instrument

All measurements were taken with a Shimadzu UV-Visible 1800 Spectrophotometer (Japan). The samples’ absorption spectra were scanned using 10 mm quartz cuvettes. The scanned spectra were manipulated using Shimadzu UV-Probe software version 2.43, accessed by Umm Al-Qura University, Makkah, Saudi Arabia.

Standard solutions

FPV and RDV stock solutions with a concentration of 100 µg/mL were prepared by weighing 10 mg of each drug powder and placing it in two separate 100-mL volumetric flasks with 50 mL ethanol, vigorously shaking, and filling to the required volume with ethanol.

Procedures

Development of calibration graphs for analytical procedure

Separate serial dilutions of FPV and RDV were made by transferring aliquots of FPV and RDV equivalent to (20–240 µg) from their respective standard solutions (100 µg /mL) into two sets of 10-mL volumetric flasks and diluting to volume with ethanol. The absorption spectra of these dilutions were scanned and recorded against a blank in the wavelength range of 200–400 nm. The recorded zero-order absorption spectra of each drug were divided by a suitable divisor spectrum from the spectra of the second drug to create the ratio spectra. A spectrum of 10 µg/mL of each drug was the optimal divisor.

Ratio difference method (RD). The calibration graphs were created by plotting the difference in amplitude values of the ratio spectra at 222 and 256 nm for FPV and 247 and 271 nm for RDV versus the drugs concentrations, and the regression equations were generated.

First derivative of ratio spectra method (1DD). Each drug’s created ratio spectra were converted to its first order derivative using ∆λ = 4 and scaling factor 100. The 1DD amplitude values for FPV and RDV were measured at 228 and 251.20 nm, respectively. To obtain the calibration graphs, the recorded values were plotted against each drug concentration, and the corresponding regression equations were generated.

Analysis of laboratory mixed solutions

Five laboratory mixed samples containing different concentrations of FPV and RDV in different ratios were made and analyzed as mentioned under the development of calibration graphs for analytical procedure.

Analysis of pharmaceutical preparations

Five Avipiravir tablets with 200 mg FPV each were weighed and finely crushed. In a 100-mL volumetric flask with 60 mL ethanol, an exact weight of powder corresponding to one tablet was added. The flask was vigorously shaken for 20 min before being filtered and ethanol-adjusted to 100 mL. Five samples of varied concentrations were obtained after further dilution with ethanol, and the process outlined under the development of calibration graphs for analytical procedure was followed.

In contrast, the contents of three Remdesivir-EVA PHARM vials (100 mg RDV per 20 mL) were well mixed. An aliquot of 10 mg RDV was transferred to a 100-mL volumetric flask, properly mixed, and filled to volume with ethanol. The appropriate amounts of sample fraction were transferred into a series of 10-mL volumetric flasks, and the analytes quantities that fell within the calibration range were obtained by adding ethanol. The samples were analyzed using the procedure outlined under the development of calibration graphs for analytical procedure.

Development of calibration graphs for bioanalytical procedure

Different spiked human plasma samples of FPV and RDV were made by transferring aliquots of FPV and RDV equivalent to (15–240 µg) and (14–240 µg), respectively, from their respective standard solutions (100 µg/mL) into two sets of centrifugation tubes together with 0.1 mL of human plasma and 5 mL of acetonitrile. The tubes were shaken for 1 min on a vortex mixer and then centrifuged for 30 min. The formed supernatants were evaporated in rotary evaporator to dryness. The residues were dissolved in appropriate volume of ethanol, transferred to 10-mL volumetric flasks, and diluting to volume with ethanol. Calibration curves were created as mentioned under Development of calibration graphs for analytical procedure. During the development of the calibration curve, 1.5 µg/mL and 1.4 µg/mL were taken as the lower limit of quantification (LLOQ) for FPV and RDV, respectively, and 24 µg/mL was taken as the upper limit of quantification.

Quality control samples were prepared at four different levels (LLOQ, middle quantifiable concentration “MQC” (100%, 13.00 µg/mL), lower quantifiable concentration “LQC” (80%, 10.40 µg/mL), and high quantifiable concentration “HQC” (120%, 15.60 µg/mL) and analyzed thereafter to evaluate accuracy and precision. The matrix effect is efficiently evaluated by analyzing LQC and HQC samples six times using a plasma matrix.

Results and discussion

Spectral characteristic

Analytical chemists have recently dedicated themselves to making analytical procedures more environmentally benign and safer for humans through using solvents and chemicals that have a low impact on the environment while lowering energy consumption and waste generation. In our study, we tried to follow the principles of green analytical chemistry by using a green solvents and energy-efficient apparatus while lowering waste generation. For such considerations, we conduct the study using a UV-Vis Spectrophotometer, which utilizes energy at a rate of less than 0.1 kWh per sample and produces little waste. Practically, FPV was found to be soluble in DMSO, ethanol, methanol, and water, while RDV was soluble in DMSO, ethanol, and methanol but insoluble in water. According to a survey of solvent selection guides [62], ethanol was selected as a solvent for the analysis of the studied drugs because it was ranked among the recommended solvents (green category).

The normal UV absorption spectra of FPV and RDV overlap significantly, making their simultaneous determination extremely challenging (Fig. 2). Two ratio spectra manipulating spectrophotometric methods namely, ratio difference and first derivative of ratio spectra were used to overcome the overlap issue and quantitatively determine FPV and RDV in their laboratory mixed solutions and spiked plasma.

Theoretically, for mixture of two drugs (x) and (y), the absorption of two drugs at certain wavelength according to Beer’s law is

$${\text{A}}_{m} {\text{ = A}}_{x} {\text{ + A}}_{y} {\text{ = }}\varepsilon _{x} {\text{C}}_{x} {\text{ + }}\varepsilon _{x} {\text{C}}_{y}$$
(1)

where Am is the sum of absorbance of two drugs Ax and Ay; Ɛx and Ɛy are the molar absorptivity of two drugs at certain wavelength; Cx and Cy are the concentrations of two drugs.

For determination of drug (x) in mixture, the absorbance of drug (y) should be canceled by dividing the mixture by a known concentration of drug (y) as a divisor y° [Ay°=Ɛy° Cy°] as the following

$$\frac{{A_{m} }}{{A_{{{\text{y}} \circ }} }} = \frac{{A_{x} }}{{A_{{{\text{y}} \circ }} }} + \frac{{C_{y} }}{{C_{{{\text{y}} \circ }} }}$$
(2)

Simply the Eq. (2) can express as the following:

$${P}_{m}={P}_{x}+K$$
(3)

where K is a constant (Cy/Cy°); Pm is the ratio absorbance of the mixture to drug (y°); Px is the ratio absorbance of the drug (x) to drug (y°).

The constant (K), along with any additional instrumental error or interference from the sample matrix, will be cancelled by selecting two wavelengths (λ1 and λ2) on the obtained ratio spectrum and subtracting the amplitudes at these two points, as the following

$$\varDelta P={P}_{m1}-{P}_{m2}= \left({P}_{x1} +K\right)-\left({P}_{x2}+ K\right)={P}_{x1} -{P}_{x2}$$
(4)

where ∆P is the difference between the peak amplitude at two selected wavelengths (λ1 and λ2); Px1 and Px2 are the peak amplitudes of the ratio spectra of the drug (x) at two wavelengths, respectively.

The drug (x) can be quantitively analyzed from a mixture by plotting the ratio spectra amplitude difference at two different wavelengths against the concentration of drug (x). Similarly, if drug (x) is present, another drug (y) can be determined using the same procedure.

Accordingly, the ratio spectra of FPV and RDV were generated by dividing the normal drugs spectra by a suitable divisor spectrum (Fig. 3). Because selecting a divisor is such an important step with regards to signal-to-noise ratio and sensitivity, several FPV and RDV spectrums were tested as divisors. A spectrum of 10 µg/mL of each drug was found to be the best divisor. The ratio difference method is based on calculating the ratio spectra amplitude difference at two different wavelengths. As a result, the linearity at each wavelength must be verified. Linearity was found to be good at 222 and 256 nm for FPV and 247 and 271 nm for RDV. FPV was determined selectively in a mixture without interference from RDV using the equation derived from plotting the amplitude differences between 222 and 256 nm versus FPV concentrations. RDV, on the other hand, was determined without interference from FPV using the equation derived from plotting the amplitude differences between 247 and 271 nm versus RDV concentrations.

For first derivative of ratio spectra approach, the obtained ratio spectra of each drug were transformed to its first order derivative using ∆λ = 4 and scaling factor 100 (Fig. 4). The linearity and selectivity of the 1DD spectra of FPV and RDV at various peak amplitudes were investigated, and it was discovered that wavelengths of 228 and 251.20 nm for FPV and RDV, respectively, provided good linearity and selectivity. As a result, FPV was determined selectively in a mixture without interference from RDV using the equation derived from plotting the amplitude values at 228 nm versus FPV concentrations. RDV, on the other hand, was determined selectively in a mixture without interference from FPV using the equation derived from plotting the amplitude values at 251.20 nm versus RDV concentrations.

Fig. 2
figure 2

Absorption spectra of FPV (15 µg/mL) and RDV (15 µg/mL)

Full size image
Fig. 3
figure 3

a Ratio spectra of FPV (2–24 µg/mL) using 10 µg/mL of RDV as a divisor; b Ratio spectra of RDV (2–24 µg/mL) using 10 µg/mL of FPV as a divisor

Full size image
Fig. 4
figure 4

a 1DD spectra of FPV (2–24 µg/mL) using 10 µg/mL of RDV as a divisor; b 1DD spectra of RDV (2–24 µg/mL) using 10 µg/mL of FPV as a divisor

Full size image

Method validation

Validation of Analytical Procedures

The procedures used were validated in accordance with ICH Q2 (R1) recommendations [63]. The data in Table 1 indicate the limits of detection (LOD) & quantitation (LOQ), accuracy, precision, linearity, and regression parameters. The methods used indicated satisfactory linearity in the concentration ranges of 2–24 µg/mL for both FVP and RDV, with acceptable accuracy and precision. The methods were discovered to be sensitive, with LOD values of 0.390 µg/mL and 0.336 µg/mL for FPV and RDV, respectively, in the ratio difference method, and 0.402 µg/mL and 0.331 µg/mL for FPV and RDV, respectively, in the first derivative of ratio spectra method. The described procedures demonstrated successful applicability in terms of selectivity for measurement of FPV and RDV in their laboratory mixed solutions without interference from each other (Table 2), as well as in pharmaceutical dosage forms (Table 3), without interference from excipients, as confirmed by standard addition technique results (Table 3). The obtained results were statistically compared to the reported methods [17, 37] using the student’s t-test and F-test. The results found no statistically significant difference between the methods (Table 3).

Table 1 Regression and validation data for quantitative analysis of FPV and RDV by the proposed methods
Full size table
Table 2 Application of the proposed methods for the determnation of FPV and RDV in their laboratory mixed solutions
Full size table
Table 3 Quantitative determination of FPV and RDV in pharmaceutical preparations using the proposed methods, as well as the results of using the standard addition technique, with statistical comparison to the reported methods
Full size table

Validation of Bioanalytical Procedures

The validation of the developed methods was done as per ICH M10 guidelines [64], including linearity, the lower limit of quantification (LLOQ), accuracy, precision, and matrix effect. Linearity was evaluated at seven calibration standard levels. The linearity ranges for FVP and RDV were 1.5–24 g/mL and 1.4–24 g/mL, respectively, with a coefficient of determination (r2) ≥ 0.9971 (Table 4). The LLOQ is the lowest amount of FVP and RDV that can be quantitatively determined and calculated with acceptable precision and accuracy. As listed in Table 4, the LLOQs of FVP and RDV were 1.5 µg/mL and 1.4 µg/mL, respectively.

The accuracy of the described methods was performed based on by calculating the mean percentage recovery of FVP and RDV from four quality control samples including LLOQ, middle quantifiable concentration (MQC) (100%, 13.00 µg/mL), lower quantifiable concentration (LQC) (80%, 10.40 µg/mL), and high quantifiable concentration (HQC) (120%, 15.60 µg/mL). Triple measurement of the concentrations was done using the calibration graph of the spiked plasma sample and the mean percent recovery was calculated. The calculated percentage recovery of FVP and RDV in the spiked plasma was found to be greater than 95% demonstrating that the described method was highly accurate (Table 4).

Precision of the described methods was studied through calculating the percent of relative standard deviation for triplicate determination of LLOQ, LQC, MQC and HQC values for every drug within one day for repeatability and on three successive days for Inter mediate precision. The small values of %RSD demonstrated high precision of the proposed models as listed in Table 4.

Matrix effect is defined as the change in the determined compound response due to interfering components in the sample matrix. So, matrix effect is efficiently evaluated by analyzing LQC and HQC samples six times using plasma matrix. The accuracy and precision should be in between ± 15%. The percentage recovery and %RSD was calculated. The assessed percentage recovery was found to be above 95% for all samples indicating noninterference of any unidentified compound in the sample matrix. Furthermore, the %RSD was less than 2. which confirmed absence of a plasma matrix effect on the drugs under the study and subsequent applicability to be used in bioanalysis as listed in Table 4.

Table 4 Bioanalytical validation parameters for quantitative analysis of FPV and RDV by the proposed methods
Full size table

Greenness evaluation

The evaluation of the described spectrophotometric methods in the context of green analytical chemistry was performed using three greenness assessment metrics, namely the national environmental method index (NEMI), the analytical eco-scale, and the analytical greenness metric (AGREE). Additionally, a comparison of the described methods greenness to the reported UPLC method was carried out.

The national environmental method index (NEMI) is the first reported qualitative greenness assessment tool. It based on a simple pictogram of four quadrants represents four criteria (amount of waste generated, reagents that are persistent, bioaccumulative, or toxic (PBT), consumption of hazardous, whether the conditions are corrosive). These criteria are evaluated in a binary manner: if a criterion’s value is satisfied, the corresponding section of the pictogram is filled in with green colour; otherwise, it stays uncolored. The described spectrophotometric methods met the four criteria and were shaded green in the four quadrants of the pictogram because ethanol was not reported as a PBT or hazardous reagent, the procedures were not performed in corrosive pH media, and the amount of waste generated was less than 50 g/sample (Table 5). In contrast, the reported UPLC method had three out of four quadrants colored green due to the presence of hazardous solvents in the mobile phase. As a result, the spectrophotometric approaches presented here are greener than the reported UPLC method.

The analytical eco-scale is a semi quantitative metric built on the concept that ideal green analysis has a value of 100. Penalty points (PPs) are assigned for each analytical procedure parameters (amount of reagents, hazards, energy and waste) deviated from ideal green analysis. The penalty points of whole procedure parameters are summed and subtracted from the basis of 100. More than 75 score is excellent green analysis, less than 50 score is inadequate green analysis, and between 50 and 75 score is acceptable green analysis. The calculated analytical eco-score of the described spectrophotometric methods (93 score) versus the reported UPLC method (83 score) supported the NEMI results and favored the spectrophotometric method, which uses just ethanol as a solvent and has no occupational hazards (Table 5).

The analytical greenness measure (AGREE) is a user-friendly software that uses the twelve-significance principle of green analytical chemistry as input criterion. Each of the twelve inputs is scored on a common scale ranging from 0 to 1 and mirrored on the intuitive red-yellow-green colour scale. Furthermore, the weight of each input criterion is assigned according to its importance in the procedure, and this is reflected by the width of its corresponding segment. The output is a clock-like graph, with the overall score and color representation in the middle. The perfect analysis has a score of one and is represented by a dark green color. The AGREE pictogram in Table 5 displayed the ultimate score (0.75) of the described spectrophotometric methods, indicating excellent green analysis.

Table 5 Greenness evaluation and comparison of the developed methods and reported one
Full size table

Conclusion

In this work, we developed two green UV spectrophotometric methods; ratio difference and first derivative of ratio spectra methods for the analysis of FPV and RDV in spiked plasma. Overall, the two methods were found to be simple, accurate and do not require sophisticated techniques or instruments. They are also sensitive and selective, making them suitable for routine analysis of FPV and RDV in plasma. The ratio difference method is simpler than the first derivative of ratio spectra method because it does not require critical measurements at fixed wavelengths or any derivative calculation. The adherence of the developed method to the principles of green analytical chemistry was evaluated using NEMI, the analytical eco-scale, and AGREE tool. The developed methods showed a closely adherence to the principles of green analytical chemistry when compared to the reported UPLC method, which utilized hazardous reagents in the mobile phase and generated more waste.

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Abbreviations

FPV:

Favipiravir

RDV:

Remdesivir

RD:

Ratio difference method

1DD:

First derivative of ratio spectra method

NEMI:

National Environmental Method Index.

References

  1. Martinez MA. Efficacy of repurposed antiviral drugs: lessons from COVID-19. Drug Discovery Today. 2022;27:1954–60. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.drudis.2022.02.012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Swathi K, Nikitha B, Chandrakala B, Lakshmanadevi K, Malleswari M. Repurposing antiviral drugs on recently emerged viral infections: a review article. Mater Today: Proc. 2021. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.matpr.2021.03.143.

    Article  PubMed  Google Scholar 

  3. Srivastava K, Singh MK. Drug repurposing in COVID-19: a review with past, present and future. Metab Open. 2021;12:100121. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.metop.2021.100121.

    Article  CAS  Google Scholar 

  4. Li X, Peng T. Strategy, progress, and challenges of drug repurposing for efficient antiviral discovery. Front Pharmacol. 2021;12:660710. https://doiorg.publicaciones.saludcastillayleon.es/10.3389/fphar.2021.660710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front Pharmacol. 2021;12:704205. https://doiorg.publicaciones.saludcastillayleon.es/10.3389/fphar.2021.704205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Al-Ardhi FM, Novotny L, Alhunayan A, Al-Tannak NF. Comparison of remdesivir and favipiravir-the anti-covid-19 agents mimicking purine RNA constituents. Biomed Pap Med Fac Palacky Univ Olomouc Czech Repub. 2022;166:12–20. https://doiorg.publicaciones.saludcastillayleon.es/10.5507/bp.2021.063.

    Article  Google Scholar 

  7. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11:1–11. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/s41598-021-90551-6.

    Article  CAS  Google Scholar 

  8. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS cent Sci. 2020;6:672–83. https://doiorg.publicaciones.saludcastillayleon.es/10.1021/acscentsci.0c00489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Taha HR, Keewan N, Slati F, Al-Sawalha NA. Remdesivir: a closer look at its effect in COVID-19 pandemic. Pharmacology. 2021;106:462–8. https://doiorg.publicaciones.saludcastillayleon.es/10.1159/000518440.

    Article  CAS  PubMed  Google Scholar 

  10. Chiba S, Kiso M, Nakajima N, Iida S, Maemura T, Kuroda M, Sato Y, Ito M, Okuda M, Yamada S, Iwatsuki-Horimoto K. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 effectively reduces SARS-CoV-2 replication in the lungs of the syrian Hamster model. Mbio. 2022;13:e03044–21. https://doiorg.publicaciones.saludcastillayleon.es/10.1128/mbio.03044-21.

    Article  CAS  PubMed Central  Google Scholar 

  11. Abdallah IA, Hammad SF, Bedair A, Elshafeey AH, Mansour FR. Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV. Bioanal. 2021;14:205–16. https://doiorg.publicaciones.saludcastillayleon.es/10.4155/bio-2021-0219.

    Article  CAS  Google Scholar 

  12. Mikhail IE, Elmansi H, Belal F, Ibrahim AE. Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens. Microchem J. 2021;165:106189. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.microc.2021.106189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bulduk İ. HPLC-UV method for quantification of favipiravir in pharmaceutical formulations. Acta Chromatogr. 2021;33:209–15. https://doiorg.publicaciones.saludcastillayleon.es/10.1556/1326.2020.00828.

    Article  CAS  Google Scholar 

  14. Marzouk HM, Rezk MR, Gouda AS, Abdel-Megied AM. A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling. Microchem J. 2022;172:106917. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.microc.2021.106917.

    Article  CAS  PubMed  Google Scholar 

  15. Bulduk İ. Comparison of HPLC and UV Spectrophotometric Methods for quantification of Favipiravir in Pharmaceutical Formulations. Iran J Pharm Res. 2021;20:57–65. https://doiorg.publicaciones.saludcastillayleon.es/10.22037/ijpr.2020.114199.14725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Megahed SM, Habib AA, Hammad SF, Kamal AH. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: application to spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2021;249:119241. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2020.119241.

    Article  CAS  PubMed  Google Scholar 

  17. Panchale WA, Bisen SB, Manwar JV, Bakal RL, Tidke TV, Paithankar MN, Vakhare AG. Development of visible spectrophotometric methods for the analysis of favipiravir in pure drug and tablet formulation. GSC Biol Pharm Sci. 2022;20:184–95. https://doiorg.publicaciones.saludcastillayleon.es/10.30574/gscbps.2022.20.2.0320.

    Article  CAS  Google Scholar 

  18. Mohamed MA, Eldin GM, Ismail SM, Zine N, Elaissari A, Jaffrezic-Renault N, Errachid A. Innovative electrochemical sensor for the precise determination of the new antiviral COVID-19 treatment Favipiravir in the presence of coadministered drugs. J Electroanal Chem. 2021;895:115422. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.jelechem.2021.115422.

    Article  CAS  Google Scholar 

  19. El-Wekil MM, Hayallah AM, Abdelgawad MA, Shahin RY. Nanocomposite of gold nanoparticles@ nickel disulfide-plant derived carbon for molecularly imprinted electrochemical determination of favipiravir. J Electroanal Chem. 2022;922:116745. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.jelechem.2022.116745.

    Article  CAS  Google Scholar 

  20. Allahverdiyeva S, Yunusoğlu O, Yardım Y, Şentürk Z. First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: a study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode. Anal Chim Acta. 2021;1159:338418. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.aca.2021.338418.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mehmandoust M, Khoshnavaz Y, Tuzen M, Erk N. Voltammetric sensor based on bimetallic nanocomposite for determination of favipiravir as an antiviral drug. Microchim Acta. 2021;188:1–15. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s00604-021-05107-2.

    Article  CAS  Google Scholar 

  22. Meng C, Zhuo Q, Wang A, Liu J, Yang Z, Niu J. Efficient electrochemical oxidation of COVID-19 treatment drugs favipiravir by a novel flow-through Ti/TiO2-NTA/Ti4O7 anode. Electrochim Acta. 2022;430:141055. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.electacta.2022.141055.

    Article  CAS  Google Scholar 

  23. Saraya RE, Deeb SE, Salman BI, Ibrahim AE. Highly sensitive high-performance thin‐layer chromatography method for the simultaneous determination of Molnupiravir, Favipiravir, and Ritonavir in pure forms and pharmaceutical formulations. J Sep Sci. 2022;45:2582–90. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/jssc.202200178.

    Article  CAS  PubMed  Google Scholar 

  24. Ramzy S, Abdelazim AH, Osman AO, Hasan MA. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2022;281:121625. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2022.121625.

    Article  CAS  PubMed  Google Scholar 

  25. El Sharkasy ME, Tolba MM, Belal F, Walash M, Aboshabana R. Quantitative analysis of favipiravir and hydroxychloroquine as FDA-approved drugs for treatment of COVID‐19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids. Luminescence. 2022;37:953–64. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/bio.4240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Emam AA, Abdelaleem EA, Abdelmomen EH, Abdelmoety RH, Abdelfatah RM. Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 patient’s plasma. Microchem J. 2022;179:107580. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.microc.2022.107580.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Noureldeen DA, Boushra JM, Lashien AS, Hakiem AFA, Attia TZ. Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs “Remdesivir and Favipiravir”: Green assessment with application to pharmaceutical formulations and human plasma. Microchem J. 2022;174:107101. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.microc.2021.107101.

    Article  CAS  PubMed  Google Scholar 

  28. El-Awady M, Elmansi H, Belal F. Insights on the quantitative concurrent fluorescence-based analysis of Anti-COVID-19 drugs Remdesivir and Favipiravir. J Fluoresc. 2022;32:1941–8. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s10895-022-02998-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ibrahim AE, Deeb SE, Abdelhalim EM, Al-Harrasi A, Sayed RA. Green Stability Indicating Organic Solvent-Free HPLC determination of Remdesivir in Substances and Pharmaceutical Dosage Forms. Separations. 2021;8:243. https://doiorg.publicaciones.saludcastillayleon.es/10.3390/separations8120243.

    Article  CAS  Google Scholar 

  30. Bulduk I, Akbel E. A comparative study of HPLC and UV spectrophotometric methods for remdesivir quantification in pharmaceutical formulations. J Taibah Univ Sci. 2021;15:507–13. https://doiorg.publicaciones.saludcastillayleon.es/10.1080/16583655.2021.1991737.

    Article  Google Scholar 

  31. Abo-Gharam AH, El-Kafrawy DS. Eco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug remdesivir: study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS. Sustainable Chem Pharm. 2022;29:100744. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.scp.2022.100744.

    Article  CAS  Google Scholar 

  32. Hamdy MMA, Abdel Moneim MM, Kamal MF. Accelerated stability study of the ester prodrug remdesivir: recently FDA-approved Covid‐19 antiviral using reversed‐phase‐HPLC with fluorimetric and diode array detection. Biomed Chromatogr. 2021;35:e5212. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/bmc.5212.

    Article  CAS  PubMed  Google Scholar 

  33. Pasupuleti RR, Tsai PC, Ponnusamy VK, Pugazhendhi A. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients. Process Biochem. 2021;102:150–6. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.procbio.2020.12.014.

    Article  CAS  PubMed  Google Scholar 

  34. Reddy HR, Pratap SR, Chandrasekhar N, Shamshuddin SZM. A Novel Liquid Chromatographic Method for the quantitative determination of Degradation Products in Remdesivir Injectable Drug product. J Chromatogr Sci. 2022;60:194–200. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/chromsci/bmab042.

    Article  CAS  PubMed  Google Scholar 

  35. Elmansi H, Ibrahim AE, Mikhail IE, Belal F. Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma. Anal Methods. 2021;13:2596–602. https://doiorg.publicaciones.saludcastillayleon.es/10.1039/D1AY00469G.

    Article  CAS  PubMed  Google Scholar 

  36. Attia TZ, Boushra JM, Abdel Hakiem AF, Lashien AS, Noureldeen DA. Spectrofluorimetric determination of the Anti-Covid 19 Agent; Remdesivir in Vials and Spiked Human plasma. Luminescence. 2022;37:1192–9. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/bio.4274.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Abdelazim AH, Ramzy S. Spectrophotometric quantitative analysis of remdesivir using acid dye reagent selected by computational calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2022;276:121188. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2022.121188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Deb S, Reeves AA, Hopefl R, Bejusca R. ADME and pharmacokinetic properties of remdesivir: its drug interaction potential. Pharmaceuticals. 2021;14:655. https://doiorg.publicaciones.saludcastillayleon.es/10.3390/ph14070655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lotfy HM, Hagazy MAM. Comparative study of novel spectrophotometric methods manipulating ratio spectra: an application on pharmaceutical ternary mixture of omeprazole, tinidazole and clarithromycin. Spectrochim Acta A Mol Biomol Spectrosc. 2012;96:259–70. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2012.04.095.

    Article  CAS  PubMed  Google Scholar 

  40. Abdelazim AH, Ramzy S, Abdel-Monem AH, Almrasy AA, Abdel-Fattah A, Shahin M. Quantitative spectrophotometric analysis of Celecoxib and Tramadol in their Multimodal Analgesia Combination Tablets. J AOAC Int. 2022;105:1479–83. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/jaoacint/qsac049.

    Article  PubMed  Google Scholar 

  41. Ramzy S, Abdelazim AH, Shahin M. Quantitative analysis of two pharmaceutical combinations containing amlodipine with either bisoprolol or candesartan using different UV spectrophotometric methods. J AOAC Int. 2022;105:1200–4. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/jaoacint/qsac018.

    Article  PubMed  Google Scholar 

  42. Salinas F, Nevado JB, Mansilla AE. A new spectrophotometric method for quantitative multicomponent analysis resolution of mixtures of salicylic and salicyluric acids. Talanta. 1990;37:347–51. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/0039-9140(90)80065-N.

    Article  CAS  PubMed  Google Scholar 

  43. Abdelazim AH, Ramzy S. Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules. BMC Chem. 2022;16:1–8. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13065-022-00850-w.

    Article  CAS  Google Scholar 

  44. Keith LH, Gron LU, Young JL. Green analytical methodologies. Chem Rev. 2007;107:2695–708. https://doiorg.publicaciones.saludcastillayleon.es/10.1021/cr068359e.

    Article  CAS  PubMed  Google Scholar 

  45. Ramzy S, Abdelazim AH, Hasan MA. Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma. BMC Chem. 2022;16:1–11. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13065-022-00855-5.

    Article  CAS  Google Scholar 

  46. Abdelazim AH, Abourehab MA, Abd Elhalim LM, Almrasy AA, Ramzy S. Different spectrophotometric methods for simultaneous determination of lesinurad and allopurinol in the new FDA approved pharmaceutical preparation; additional greenness evaluation. Spectrochim Acta A Mol Biomol Spectrosc. 2023;285:121868. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2022.121868.

    Article  CAS  PubMed  Google Scholar 

  47. Gałuszka A, Migaszewski ZM, Konieczka P, Namieśnik J. Analytical Eco-Scale for assessing the greenness of analytical procedures. TrAC. Trends Anal Chem. 2012;37:61–72. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.trac.2012.03.013.

    Article  CAS  Google Scholar 

  48. Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE—Analytical GREEnness metric approach and software. Anal chem. 2020;92:10076–82. https://doiorg.publicaciones.saludcastillayleon.es/10.1021/acs.analchem.0c01887.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Prajapati P, Patel A, Shah S. DoE-Based Analytical Quality Risk Management for enhanced AQbD Approach to economical and eco-friendly RP-HPLC method for synchronous estimation of multiple FDC products of antihypertensive drugs. J Chromatogr Sci. 2022;60(8):786–99. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/chromsci/bmab123.

    Article  CAS  PubMed  Google Scholar 

  50. Prajapati P, Shahi A, Acharya A, Shah S. Chemometric and design of experiments-based analytical quality by design and green chemistry approaches to multipurpose high-pressure liquid chromatographic method for synchronous estimation of multiple fixed-dose combinations of Azilsartan Medoxomil. J AOAC Int. 2022. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/jaoacint/qsac086.

    Article  PubMed  Google Scholar 

  51. Prajapati PB, Radadiya K, Shah SA. Quality risk management based: analytical quality by design approach to eco-friendly and versatile chromatography method for simultaneous estimation of multiple fixed-dose-combination products of anti-diabetic drugs. J Pharm Innov. 2020. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s12247-020-09506-5.

    Article  Google Scholar 

  52. Prajapati P, Shah H, Shah SA. Implementation of QRM and DoE-based quality by design approach to VEER chromatography method for simultaneous estimation of multiple combined dosage forms of paracetamol. J Pharm Innov. 2020. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s12247-020-09490-w.

    Article  Google Scholar 

  53. Prajapati PB, Bodiwala KB, Shah SA. Analytical quality-by-design approach for the stability study of thiocolchicoside by eco-friendly chromatographic method. J Planar Chromatogr–Mod TLC. 2018;31(6):477–87. https://doiorg.publicaciones.saludcastillayleon.es/10.1556/1006.2018.31.6.8.

    Article  CAS  Google Scholar 

  54. Prajapati P, Tamboli J, Surati P, Mishra A. Risk assessment-based enhanced analytical quality-by-design approach to eco-friendly and economical multicomponent spectrophotometric methods for simultaneous estimation of montelukast sodium and bilastine. J AOAC Int. 2021;104:1453–63. https://doiorg.publicaciones.saludcastillayleon.es/10.1093/jaoacint/qsab089.

    Article  PubMed  Google Scholar 

  55. Prajapati P, Patel D, Shah S. Design of experiments (DoE)-based enhanced quality by design approach to hydrolytic degradation kinetic study of capecitabine by eco-friendly stability-indicating UV-visible spectrophotometry. Am J PharmTech Res. 2020;10:115–33. https://doiorg.publicaciones.saludcastillayleon.es/10.46624/ajptr.2020.v10.i6.008.

    Article  CAS  Google Scholar 

  56. Abdelazim AH, Abourehab MA, Abd Elhalim LM, Almrasy AA, Ramzy S. Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form. Spectrochim Acta Part A. 2023;285:121911. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2022.121911.

    Article  CAS  Google Scholar 

  57. Abdelazim AH, Abourehab MA, Abd Elhalim LM, Almrasy AA, Ramzy S. Different spectrophotometric methods for simultaneous determination of lesinurad and allopurinol in the new FDA approved pharmaceutical preparation; additional greenness evaluation. Spectrochim Acta Part A. 2022;285:121868. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.saa.2022.121868.

    Article  CAS  Google Scholar 

  58. Abourehab MAS, Shahin MHK, Sheikh RE, Ellateif A, Fawzi SM, Gouda AA. Utilization of N-bromosuccinimide for the sensitive spectrophotometric determination of pipazethate HCl as antitussive drug in pure and dosage forms. Ann Pharm Fr. 2021;79:652–63. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.pharma.2021.02.008.

    Article  CAS  PubMed  Google Scholar 

  59. Kassem MA, Guesmi NE. Sensitive kinetic spectrophotometric determination of Cyclobenzaprine HCl in pure form and pharmaceutical formulations. Anal Chem Lett. 2016;6:657–68. https://doiorg.publicaciones.saludcastillayleon.es/10.1080/22297928.2016.1249517.

    Article  CAS  Google Scholar 

  60. Gouda AA, Hamdi AY, El Sheikh R, Abd Ellateif AE, Badahdah NA, Alzuhiri ME, Saeed E. Development and validation of spectrophotometric methods for estimation of antimigraine drug eletriptan hydrobromide in pure form and pharmaceutical formulations. Ann Pharm Fr. 2021;79:395–408. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.pharma.2020.11.002.

    Article  CAS  PubMed  Google Scholar 

  61. Hameed AM. An eco-friendly ultrasound-assisted deep eutectic solvent-based liquid–phase microextraction method for enrichment and quantification of nickel in environmental samples. J Umm Al-Qura Univ Appl Sci. 2022. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s43994-022-00009-2.

    Article  Google Scholar 

  62. Prat D, Hayler J, Wells A. A survey of solvent selection guides. Green Chemi. 2014;16:4546–51. https://doiorg.publicaciones.saludcastillayleon.es/10.1039/C4GC01149J.

    Article  CAS  Google Scholar 

  63. Branch SK. Guidelines from the international conference on harmonisation (ICH). J Pharm Biomed Anal. 2005;38:798–805. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.jpba.2005.02.037.

    Article  CAS  PubMed  Google Scholar 

  64. Guideline IH. Bioanalytical method validation M10. European Medicines Agency: Amsterdam, The Netherlands. 2019 Feb.

Download references

Acknowledgements

The authors would like to thank the Deanship of scientific research at Umm Al-Qura University for supporting this work under Grant code: (23UQU4280448DSR002).

Funding

This work was funded by the Deanship of scientific research at Umm Al-Qura University under Grant Code (23UQU4280448DSR002).

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, College of Pharmacy, Umm Al-Qura University, Makkah, 21955, Saudi Arabia

    Afnan S. Batubara

  2. Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, 11751, Egypt

    Ahmed H. Abdelazim, Ahmed A. Almrasy & Sherif Ramzy

  3. Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt

    Mohammed Gamal

Authors
  1. Afnan S. Batubara
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Ahmed H. Abdelazim
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Ahmed A. Almrasy
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Mohammed Gamal
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Sherif Ramzy
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

ASB: Data analysis, Review and Editing. AHA: Investigation, Methodology, Reviewing and Editing. AAA: Methodology. MG: Data analysis, Review and editing. SR: Study design, Data curation, Formal analysis, Methodology and Writing the original manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Sherif Ramzy.

Ethics declarations

Ethics approval and consent to participate

This work was approved by the Committee of Research Ethics in the Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Batubara, A.S., Abdelazim, A.H., Almrasy, A.A. et al. Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation. BMC Chemistry 17, 58 (2023). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13065-023-00967-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13065-023-00967-6

Keywords

BMC Chemistry

ISSN: 2661-801X

Contact us